JP2024518413A5 - - Google Patents

Info

Publication number
JP2024518413A5
JP2024518413A5 JP2023568340A JP2023568340A JP2024518413A5 JP 2024518413 A5 JP2024518413 A5 JP 2024518413A5 JP 2023568340 A JP2023568340 A JP 2023568340A JP 2023568340 A JP2023568340 A JP 2023568340A JP 2024518413 A5 JP2024518413 A5 JP 2024518413A5
Authority
JP
Japan
Prior art keywords
composition according
nls
sequence
polypeptide
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023568340A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024518413A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/028208 external-priority patent/WO2022236147A1/en
Publication of JP2024518413A publication Critical patent/JP2024518413A/ja
Publication of JP2024518413A5 publication Critical patent/JP2024518413A5/ja
Pending legal-status Critical Current

Links

JP2023568340A 2021-05-06 2022-05-06 修飾ヌクレアーゼ Pending JP2024518413A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163185315P 2021-05-06 2021-05-06
US63/185,315 2021-05-06
US202263315483P 2022-03-01 2022-03-01
US63/315,483 2022-03-01
PCT/US2022/028208 WO2022236147A1 (en) 2021-05-06 2022-05-06 Modified nucleases

Publications (2)

Publication Number Publication Date
JP2024518413A JP2024518413A (ja) 2024-05-01
JP2024518413A5 true JP2024518413A5 (https=) 2025-05-13

Family

ID=81975392

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023568340A Pending JP2024518413A (ja) 2021-05-06 2022-05-06 修飾ヌクレアーゼ

Country Status (4)

Country Link
US (2) US20260009009A1 (https=)
JP (1) JP2024518413A (https=)
CA (1) CA3218053A1 (https=)
WO (1) WO2022236147A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240126870A (ko) 2021-12-22 2024-08-21 캠프4 테라퓨틱스 코포레이션 조절 rna들을 표적으로 하는 안티센스 올리고뉴클레오티드를 사용한 유전자 전사의 조절
AU2024270764A1 (en) 2023-05-15 2025-12-04 Nchroma Bio, Inc. Compositions and methods for epigenetic regulation of hbv gene expression
WO2026046724A1 (en) * 2024-08-30 2026-03-05 Cellectis Sa Tale protein scaffolds involving fusions of monopartite and bipartite nls

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
EP3390624A4 (en) * 2015-12-18 2019-07-10 The Regents of The University of California Modified site-directed modifying polypeptides and methods of use thereof
US9896696B2 (en) 2016-02-15 2018-02-20 Benson Hill Biosystems, Inc. Compositions and methods for modifying genomes
US9982279B1 (en) 2017-06-23 2018-05-29 Inscripta, Inc. Nucleic acid-guided nucleases
US10011849B1 (en) * 2017-06-23 2018-07-03 Inscripta, Inc. Nucleic acid-guided nucleases
EP3916086A1 (en) * 2017-06-23 2021-12-01 Inscripta, Inc. Nucleic acid-guided nucleases
US11649442B2 (en) * 2017-09-08 2023-05-16 The Regents Of The University Of California RNA-guided endonuclease fusion polypeptides and methods of use thereof
EP3724326A1 (en) * 2017-12-11 2020-10-21 Editas Medicine, Inc. Cpf1-related methods and compositions for gene editing
EP3821008A1 (en) * 2018-07-12 2021-05-19 Keygene N.V. Type v crispr/nuclease-system for genome editing in plant cells
WO2020086475A1 (en) * 2018-10-22 2020-04-30 Inscripta, Inc. Engineered enzymes
WO2020092057A1 (en) * 2018-10-30 2020-05-07 Yale University Compositions and methods for rapid and modular generation of chimeric antigen receptor t cells
EP3874051A1 (en) * 2018-10-31 2021-09-08 Novozymes A/S Genome editing by guided endonuclease and single-stranded oligonucleotide
WO2020109412A1 (en) * 2018-11-28 2020-06-04 Keygene N.V. Targeted enrichment by endonuclease protection
WO2021050601A1 (en) * 2019-09-09 2021-03-18 Scribe Therapeutics Inc. Compositions and methods for use in immunotherapy
JP7689949B2 (ja) * 2019-10-03 2025-06-09 アーティサン ディベロップメント ラブズ インコーポレイテッド 操作されたデュアルガイド核酸を有するｃｒｉｓｐｒシステム
WO2021074191A1 (en) * 2019-10-14 2021-04-22 KWS SAAT SE & Co. KGaA Mad7 nuclease in plants and expanding its pam recognition capability
AU2021216418A1 (en) 2020-02-05 2022-09-01 Danmarks Tekniske Universitet Compositions and methods for targeting, editing or modifying human genes

Similar Documents

Publication Publication Date Title
JP2024518413A5 (https=)
KR101817482B1 (ko) 캄필로박터 제주니 crispr/cas 시스템 유래 rgen을 이용한 유전체 교정
Weiss et al. RNA recognition by arginine‐rich peptide motifs
Scott et al. Purification of the rep protein of Escherichia coli. An ATPase which separates duplex DNA strands in advance of replication.
JP2023516226A5 (https=)
Petty et al. Infectious barley stripe mosaic virus RNA transcribed in vitro from full-length genomic cDNA clones
JP2022545385A5 (https=)
Van der Ploeg et al. Antigenic variation in African trypanosomes
HEYDEN et al. Single RNA polymerase binding site isolated
JP2022519882A5 (https=)
CN106191071A (zh) 一种CRISPR‑Cas9系统及其用于治疗乳腺癌疾病的应用
JP2024535672A5 (https=)
JP2025073123A5 (https=)
CN114144519B (zh) 单碱基置换蛋白以及包含其的组合物
CA2365984A1 (en) Antisense oligonucleotides comprising universal and/or degenerate bases
Cerritelli et al. Cloning, expression, and mapping of ribonucleases H of human and mouse related to bacterial RNase HI
JP2022513459A5 (https=)
JP2024511131A5 (https=)
JP2024529425A5 (https=)
JP2024542995A5 (https=)
CN110331147A (zh) 一种mRNA的制备方法及其在肿瘤治疗中的应用
US20200224194A1 (en) Expression systems that facilitate nucleic acid delivery and methods of use
WO2000066722B1 (en) Collection of prokaryotic dna for two hybrid systems helicobacter pylori protein-protein interactions and application thereof
Inouye et al. Two independent retrons with highly diverse reverse transcriptases in Myxococcus xanthus.
KR20180128864A (ko) 매칭된 5' 뉴클레오타이드를 포함하는 가이드 rna를 포함하는 유전자 교정용 조성물 및 이를 이용한 유전자 교정 방법